Paradigm Biopharmaceuticals (ASX:PAR) Total Liabilities : A$11.24 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Paradigm Biopharmaceuticals Total Liabilities?

Paradigm Biopharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2023 was A$11.24 Mil.

Paradigm Biopharmaceuticals's quarterly Total Liabilities declined from Dec. 2022 (A$14.84 Mil) to Jun. 2023 (A$13.39 Mil) and declined from Jun. 2023 (A$13.39 Mil) to Dec. 2023 (A$11.24 Mil).

Paradigm Biopharmaceuticals's annual Total Liabilities increased from Jun. 2021 (A$6.52 Mil) to Jun. 2022 (A$8.38 Mil) and increased from Jun. 2022 (A$8.38 Mil) to Jun. 2023 (A$13.39 Mil).

Paradigm Biopharmaceuticals Total Liabilities Historical Data

The historical data trend for Paradigm Biopharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paradigm Biopharmaceuticals Total Liabilities Chart

Paradigm Biopharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Liabilities

Get a 7-Day Free Trial

2.71

4.18

6.52

8.38

13.39

Paradigm Biopharmaceuticals Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Liabilities	Get a 7-Day Free Trial												14.58	8.38	14.84	13.39	11.24

Paradigm Biopharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Paradigm Biopharmaceuticals's Total Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	13.042	+	(0.237	+	-3.4694469519536E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0.113)
	=	13.39

Total Liabilities	=	Total Assets (A: Jun. 2023 )	-	Total Equity (A: Jun. 2023 )
	=	67.07	-	53.678
	=	13.39

Paradigm Biopharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	10.922	+	(0.177	+	0.141
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	11.24

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	45.039	-	33.799
	=	11.24

Paradigm Biopharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Paradigm Biopharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Paradigm Biopharmaceuticals (ASX:PAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (ASX:PAR) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

PBIGF:USA

Address

500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000

Website

https://www.paradigmbiopharma.com

Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company that engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) for the lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).